These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 29294080)
1. Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres. Park J; Shim JK; Kang JH; Choi J; Chang JH; Kim SY; Kang SG Neuro Oncol; 2018 Jun; 20(7):954-965. PubMed ID: 29294080 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin. Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886 [TBL] [Abstract][Full Text] [Related]
3. Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling. Lee JS; Lee H; Jang H; Woo SM; Park JB; Lee SH; Kang JH; Kim HY; Song J; Kim SY Cells; 2020 Sep; 9(9):. PubMed ID: 32883024 [TBL] [Abstract][Full Text] [Related]
4. Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres. Park HH; Park J; Cho HJ; Shim JK; Moon JH; Kim EH; Chang JH; Kim SY; Kang SG Molecules; 2021 Jan; 26(2):. PubMed ID: 33429981 [TBL] [Abstract][Full Text] [Related]
5. Combined treatment with 2'-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness. Jeong H; Park J; Shim JK; Lee JE; Kim NH; Kim HS; Chang JH; Yook JI; Kang SG J Neurooncol; 2019 May; 143(1):69-77. PubMed ID: 30887242 [TBL] [Abstract][Full Text] [Related]
6. Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion. Kang JH; Lee SH; Lee JS; Nam B; Seong TW; Son J; Jang H; Hong KM; Lee C; Kim SY Oncotarget; 2016 Aug; 7(31):49397-49410. PubMed ID: 27384481 [TBL] [Abstract][Full Text] [Related]
7. A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres. Roh TH; Lee JH; Kim SJ; Shim JK; Park J; Yoon SJ; Teo WY; Kim SH; Chang JH; Kang SG J Neurooncol; 2022 Jan; 156(1):139-151. PubMed ID: 34811601 [TBL] [Abstract][Full Text] [Related]
8. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539 [TBL] [Abstract][Full Text] [Related]
9. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Jiang W; Finniss S; Cazacu S; Xiang C; Brodie Z; Mikkelsen T; Poisson L; Shackelford DB; Brodie C Oncotarget; 2016 Aug; 7(35):56456-56470. PubMed ID: 27486821 [TBL] [Abstract][Full Text] [Related]
10. Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres. Oh HC; Shim JK; Park J; Lee JH; Choi RJ; Kim NH; Kim HS; Moon JH; Kim EH; Chang JH; Yook JI; Kang SG J Cancer Res Clin Oncol; 2020 Nov; 146(11):2817-2828. PubMed ID: 32712753 [TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres. Kim SJ; Park SJ; Park J; Cho HJ; Shim JK; Seon J; Choi RJ; Yoon SJ; Moon JH; Kim EH; Seo EK; Kim SH; Kim HS; Teo WY; Chang JH; Yook JI; Kang SG J Neurooncol; 2022 Dec; 160(3):677-689. PubMed ID: 36396930 [TBL] [Abstract][Full Text] [Related]
12. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis. Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587 [TBL] [Abstract][Full Text] [Related]
13. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis. Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119 [TBL] [Abstract][Full Text] [Related]
14. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306 [TBL] [Abstract][Full Text] [Related]
15. Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC. Lee S; Lee JS; Seo J; Lee SH; Kang JH; Song J; Kim SY Sci Rep; 2018 Oct; 8(1):15707. PubMed ID: 30356107 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292 [TBL] [Abstract][Full Text] [Related]
17. Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules. Zhu T; Li X; Luo L; Wang X; Li Z; Xie P; Gao X; Song Z; Su J; Liang G J Transl Med; 2015 Nov; 13():356. PubMed ID: 26563263 [TBL] [Abstract][Full Text] [Related]
18. NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma. Guo Q; Han N; Shi L; Yang L; Zhang X; Zhou Y; Yu S; Zhang M Oncol Rep; 2019 Sep; 42(3):963-972. PubMed ID: 31322259 [TBL] [Abstract][Full Text] [Related]
20. Mesenchymal Stem-Like Cells Derived from the Ventricle More Effectively Enhance Invasiveness of Glioblastoma Than Those Derived from the Tumor. Park J; Lee D; Shim JK; Yoon SJ; Moon JH; Kim EH; Chang JH; Lee SJ; Kang SG Yonsei Med J; 2023 Mar; 64(3):157-166. PubMed ID: 36825341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]